Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 Apr;114(8):1529–1540. doi: 10.1111/j.1476-5381.1995.tb14936.x

Pharmacological evidence for the presence of three distinct functional endothelin receptor subtypes in the rabbit lateral saphenous vein.

S A Douglas 1, G R Beck Jr 1, J D Elliott 1, E H Ohlstein 1
PMCID: PMC1510370  PMID: 7599920

Abstract

1. Contraction of the rabbit isolated saphenous vein is mediated by a heterogeneous endothelin (ET) receptor population. This study has characterized these receptor subtypes by use of several pharmacologically distinct ET receptor agonists and antagonists. 2. ET-1, ET-3, sarafotoxin S6c (STXc) and [Ala3,11]ET-1 produced biphasic, concentration-dependent contractions of the saphenous vein, responses which were best fitted by a two-site model comprised of a high (pM) and a low (nM) affinity site. In contrast, IRL 1620 only recognized one of these sites. ET(16-21) was devoid of contractile activity. ET-1, ET-3 and STXc were equipotent at the high affinity site (pD2s of 12.0 +/- 0.2, 12.2 +/- 0.2 and 12.3 +/- 0.3) indicating that this site had the characteristics of an ETB receptor. In contrast, the low affinity site had the functional characteristics of an ETc receptor since the pD2s for ET-3 (10.2 +/- 0.3) and STXc (10.6 +/- 0.3) were significantly greater than that for ET-1 (9.1 +/- 0.1). These contractile responses were insensitive to BQ-123, confirming that ETA receptors were not involved in mediating this effect. 3. SB 209670 differentially antagonized the high affinity phases of the isopeptide concentration-response curves in a fashion dependent on the competing agonist: relative to the KB obtained against STXc (0.15 nM). SB 209670 was 10 fold less potent when ET-1 was used as the competing agonist. This differential effect was not evident at the low affinity site (KB = 38 nM). SB 209670 produced parallel, concentration-dependent rightward shifts in the concentration-response curve to STXc Ro 47-0203 was approximately 1 to 2 orders of magnitude less potent than SB 209670 at inhibiting the high affinity component of the concentration-response curve to STXc, whereas BQ-788 and Ro 46-2005 were approximately 3 orders of magnitude less potent than SB 209670. In addition to RES-701 and BQ-123, the high affinity site was insensitive to PD 142893 suggesting that it may represent an ETB2 receptor. Ro 47-0203 and SB 209670 were equipotent at inhibiting the low affinity component of the STXc concentration-response curve. Although Ro 46-2005, BQ-788, PD 142893 and RES-701 produced significant antagonism at the low affinity site, they were at least ten fold less potent than SB 209670.(ABSTRACT TRUNCATED AT 400 WORDS)

Full text

PDF
1529

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adamson J. D., Flett R. O. The Inefficacy of Sulfapyridine in Influenza. Can Med Assoc J. 1942 Feb;46(2):121–123. [PMC free article] [PubMed] [Google Scholar]
  2. Akar F., Uydes B. S., Ayrancioğlu K., Yener A., Aşlamaci S., Arsan M., Törüner A., Kanzik I. Endothelial function of human gastroepiploic artery in comparison with saphenous vein. Cardiovasc Res. 1994 Apr;28(4):500–504. doi: 10.1093/cvr/28.4.500. [DOI] [PubMed] [Google Scholar]
  3. Arai H., Hori S., Aramori I., Ohkubo H., Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990 Dec 20;348(6303):730–732. doi: 10.1038/348730a0. [DOI] [PubMed] [Google Scholar]
  4. Auguet M., Delaflotte S., Chabrier P. E., Braquet P. Characterization of endothelin receptors mediating contraction and relaxation in rabbit saphenous artery and vein. Can J Physiol Pharmacol. 1993 Oct-Nov;71(10-11):818–823. doi: 10.1139/y93-122. [DOI] [PubMed] [Google Scholar]
  5. Bax W. A., Bos E., Saxena P. R. Heterogeneity of endothelin/sarafotoxin receptors mediating contraction of the human isolated saphenous vein. Eur J Pharmacol. 1993 Aug 3;239(1-3):267–268. doi: 10.1016/0014-2999(93)91010-k. [DOI] [PubMed] [Google Scholar]
  6. Berti F., Rossoni G., Biasi G., Buschi A., Mandelli V., Tondo C. Defibrotide, by enhancing prostacyclin generation, prevents endothelin-1 induced contraction in human saphenous veins. Prostaglandins. 1990 Oct;40(4):337–350. doi: 10.1016/0090-6980(90)90099-h. [DOI] [PubMed] [Google Scholar]
  7. Bigaud M., Pelton J. T. Discrimination between ETA- and ETB-receptor-mediated effects of endothelin-1 and [Ala1,3,11,15]endothelin-1 by BQ-123 in the anaesthetized rat. Br J Pharmacol. 1992 Dec;107(4):912–918. doi: 10.1111/j.1476-5381.1992.tb13385.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Brooks D. P., dePalma P. D., Gellai M., Nambi P., Ohlstein E. H., Elliott J. D., Gleason J. G., Ruffolo R. R., Jr Nonpeptide endothelin receptor antagonists. III. Effect of SB 209670 and BQ123 on acute renal failure in anesthetized dogs. J Pharmacol Exp Ther. 1994 Nov;271(2):769–775. [PubMed] [Google Scholar]
  9. Buchan K. W., Alldus C., Christodoulou C., Clark K. L., Dykes C. W., Sumner M. J., Wallace D. M., White D. G., Watts I. S. Characterization of three non-peptide endothelin receptor ligands using human cloned ETA and ETB receptors. Br J Pharmacol. 1994 Aug;112(4):1251–1257. doi: 10.1111/j.1476-5381.1994.tb13218.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Clozel M., Breu V., Burri K., Cassal J. M., Fischli W., Gray G. A., Hirth G., Löffler B. M., Müller M., Neidhart W. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature. 1993 Oct 21;365(6448):759–761. doi: 10.1038/365759a0. [DOI] [PubMed] [Google Scholar]
  11. Clozel M., Breu V., Gray G. A., Kalina B., Löffler B. M., Burri K., Cassal J. M., Hirth G., Müller M., Neidhart W. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther. 1994 Jul;270(1):228–235. [PubMed] [Google Scholar]
  12. Clozel M., Gray G. A., Breu V., Löffler B. M., Osterwalder R. The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo. Biochem Biophys Res Commun. 1992 Jul 31;186(2):867–873. doi: 10.1016/0006-291x(92)90826-7. [DOI] [PubMed] [Google Scholar]
  13. Doherty A. M., Cody W. L., He J. X., DePue P. L., Cheng X. M., Welch K. M., Flynn M. A., Reynolds E. E., LaDouceur D. M., Davis L. S. In vitro and in vivo studies with a series of hexapeptide endothelin antagonists. J Cardiovasc Pharmacol. 1993;22 (Suppl 8):S98–102. doi: 10.1097/00005344-199322008-00027. [DOI] [PubMed] [Google Scholar]
  14. Douglas S. A., Edwards R. M., Elliott J. D., Ohlstein E. H. In vivo pharmacological characterization of the non-peptide endothelin receptor antagonist SB 209670. Br J Pharmacol. 1995 Jan;114(2):405–413. doi: 10.1111/j.1476-5381.1995.tb13241.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Douglas S. A., Hiley C. R. Endothelium-dependent mesenteric vasorelaxant effects and systemic actions of endothelin (16-21) and other endothelin-related peptides in the rat. Br J Pharmacol. 1991 Oct;104(2):311–320. doi: 10.1111/j.1476-5381.1991.tb12428.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Douglas S. A., Hiley C. R. Endothelium-dependent vascular activities of endothelin-like peptides in the isolated superior mesenteric arterial bed of the rat. Br J Pharmacol. 1990 Sep;101(1):81–88. doi: 10.1111/j.1476-5381.1990.tb12093.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Douglas S. A., Louden C., Vickery-Clark L. M., Storer B. L., Hart T., Feuerstein G. Z., Elliott J. D., Ohlstein E. H. A role for endogenous endothelin-1 in neointimal formation after rat carotid artery balloon angioplasty. Protective effects of the novel nonpeptide endothelin receptor antagonist SB 209670. Circ Res. 1994 Jul;75(1):190–197. doi: 10.1161/01.res.75.1.190. [DOI] [PubMed] [Google Scholar]
  18. Douglas S. A., Meek T. D., Ohlstein E. H. Novel receptor antagonists welcome a new era in endothelin biology. Trends Pharmacol Sci. 1994 Sep;15(9):313–316. doi: 10.1016/0165-6147(94)90019-1. [DOI] [PubMed] [Google Scholar]
  19. Douglas S. A., Vickery-Clark L. M., Ohlstein E. H. Functional evidence that balloon angioplasty results in transient nitric oxide synthase induction. Eur J Pharmacol. 1994 Apr 1;255(1-3):81–89. doi: 10.1016/0014-2999(94)90085-x. [DOI] [PubMed] [Google Scholar]
  20. Emori T., Hirata Y., Marumo F. Specific receptors for endothelin-3 in cultured bovine endothelial cells and its cellular mechanism of action. FEBS Lett. 1990 Apr 24;263(2):261–264. doi: 10.1016/0014-5793(90)81388-5. [DOI] [PubMed] [Google Scholar]
  21. Gardiner S. M., Kemp P. A., March J. E., Bennett T., Davenport A. P., Edvinsson L. Effects of an ET1-receptor antagonist, FR139317, on regional haemodynamic responses to endothelin-1 and [Ala11,15]Ac-endothelin-1 (6-21) in conscious rats. Br J Pharmacol. 1994 Jun;112(2):477–486. doi: 10.1111/j.1476-5381.1994.tb13098.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Godfraind T. Endothelin receptors in human coronary arteries. Trends Pharmacol Sci. 1994 May;15(5):136–137. doi: 10.1016/0165-6147(94)90068-x. [DOI] [PubMed] [Google Scholar]
  23. Godfraind T. Evidence for heterogeneity of endothelin receptor distribution in human coronary artery. Br J Pharmacol. 1993 Nov;110(3):1201–1205. doi: 10.1111/j.1476-5381.1993.tb13942.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Gray G. A., Löffler B. M., Clozel M. Characterization of endothelin receptors mediating contraction of rabbit saphenous vein. Am J Physiol. 1994 Mar;266(3 Pt 2):H959–H966. doi: 10.1152/ajpheart.1994.266.3.H959. [DOI] [PubMed] [Google Scholar]
  25. Harrison V. J., Randriantsoa A., Schoeffter P. Heterogeneity of endothelin-sarafotoxin receptors mediating contraction of pig coronary artery. Br J Pharmacol. 1992 Mar;105(3):511–513. doi: 10.1111/j.1476-5381.1992.tb09009.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Ihara M., Noguchi K., Saeki T., Fukuroda T., Tsuchida S., Kimura S., Fukami T., Ishikawa K., Nishikibe M., Yano M. Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci. 1992;50(4):247–255. doi: 10.1016/0024-3205(92)90331-i. [DOI] [PubMed] [Google Scholar]
  27. Ishikawa K., Ihara M., Noguchi K., Mase T., Mino N., Saeki T., Fukuroda T., Fukami T., Ozaki S., Nagase T. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci U S A. 1994 May 24;91(11):4892–4896. doi: 10.1073/pnas.91.11.4892. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Karne S., Jayawickreme C. K., Lerner M. R. Cloning and characterization of an endothelin-3 specific receptor (ETC receptor) from Xenopus laevis dermal melanophores. J Biol Chem. 1993 Sep 5;268(25):19126–19133. [PubMed] [Google Scholar]
  29. Kasai H., Takanashi M., Takasaki C., Endoh M. Pharmacological properties of endothelin receptor subtypes mediating positive inotropic effects in rabbit heart. Am J Physiol. 1994 Jun;266(6 Pt 2):H2220–H2228. doi: 10.1152/ajpheart.1994.266.6.H2220. [DOI] [PubMed] [Google Scholar]
  30. Komori K., Vanhoutte P. M. Effects of SIN-1 on electrical responses of the smooth muscle of the canine saphenous vein. J Cardiovasc Pharmacol. 1989;14 (Suppl 11):S62–S66. [PubMed] [Google Scholar]
  31. LaDouceur D. M., Flynn M. A., Keiser J. A., Reynolds E., Haleen S. J. ETA and ETB receptors coexist on rabbit pulmonary artery vascular smooth muscle mediating contraction. Biochem Biophys Res Commun. 1993 Oct 15;196(1):209–215. doi: 10.1006/bbrc.1993.2236. [DOI] [PubMed] [Google Scholar]
  32. Lee J. A., Elliott J. D., Sutiphong J. A., Friesen W. J., Ohlstein E. H., Stadel J. M., Gleason J. G., Peishoff C. E. Tyr-129 is important to the peptide ligand affinity and selectivity of human endothelin type A receptor. Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7164–7168. doi: 10.1073/pnas.91.15.7164. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. MacLean M. R., McCulloch K. M., Baird M. Endothelin ETA- and ETB-receptor-mediated vasoconstriction in rat pulmonary arteries and arterioles. J Cardiovasc Pharmacol. 1994 May;23(5):838–845. doi: 10.1097/00005344-199405000-00022. [DOI] [PubMed] [Google Scholar]
  34. Maggi C. A., Giuliani S., Patacchini R., Santicioli P., Rovero P., Giachetti A., Meli A. The C-terminal hexapeptide, endothelin-(16-21), discriminates between different endothelin receptors. Eur J Pharmacol. 1989 Jul 4;166(1):121–122. doi: 10.1016/0014-2999(89)90693-6. [DOI] [PubMed] [Google Scholar]
  35. Masaki T., Vane J. R., Vanhoutte P. M. International Union of Pharmacology nomenclature of endothelin receptors. Pharmacol Rev. 1994 Jun;46(2):137–142. [PubMed] [Google Scholar]
  36. Miller V. M., Komori K., Burnett J. C., Jr, Vanhoutte P. M. Differential sensitivity to endothelin in canine arteries and veins. Am J Physiol. 1989 Oct;257(4 Pt 2):H1127–H1131. doi: 10.1152/ajpheart.1989.257.4.H1127. [DOI] [PubMed] [Google Scholar]
  37. Moreland S., McMullen D. M., Delaney C. L., Lee V. G., Hunt J. T. Venous smooth muscle contains vasoconstrictor ETB-like receptors. Biochem Biophys Res Commun. 1992 Apr 15;184(1):100–106. doi: 10.1016/0006-291x(92)91163-k. [DOI] [PubMed] [Google Scholar]
  38. Moreland S., McMullen D., Abboa-Offei B., Seymour A. Evidence for a differential location of vasoconstrictor endothelin receptors in the vasculature. Br J Pharmacol. 1994 Jun;112(2):704–708. doi: 10.1111/j.1476-5381.1994.tb13133.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Nambi P., Elshourbagy N., Wu H. L., Pullen M., Ohlstein E. H., Brooks D. P., Lago M. A., Elliott J. D., Gleason J. G., Ruffolo R. R., Jr Nonpeptide endothelin receptor antagonists. I. Effects on binding and signal transduction on human endothelinA and endothelinB receptors. J Pharmacol Exp Ther. 1994 Nov;271(2):755–761. [PubMed] [Google Scholar]
  40. Nambi P., Pullen M., Spielman W. Species differences in the binding characteristics of [125I]IRL-1620, a potent agonist specific for endothelin-B receptors. J Pharmacol Exp Ther. 1994 Jan;268(1):202–207. [PubMed] [Google Scholar]
  41. Ohlstein E. H., Beck G. R., Jr, Douglas S. A., Nambi P., Lago M. A., Gleason J. G., Ruffolo R. R., Jr, Feuerstein G., Elliott J. D. Nonpeptide endothelin receptor antagonists. II. Pharmacological characterization of SB 209670. J Pharmacol Exp Ther. 1994 Nov;271(2):762–768. [PubMed] [Google Scholar]
  42. Ohlstein E. H., Nambi P., Douglas S. A., Edwards R. M., Gellai M., Lago A., Leber J. D., Cousins R. D., Gao A., Frazee J. S. SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist. Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8052–8056. doi: 10.1073/pnas.91.17.8052. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Panek R. L., Major T. C., Hingorani G. P., Doherty A. M., Taylor D. G., Rapundalo S. T. Endothelin and structurally related analogs distinguish between endothelin receptor subtypes. Biochem Biophys Res Commun. 1992 Mar 16;183(2):566–571. doi: 10.1016/0006-291x(92)90519-q. [DOI] [PubMed] [Google Scholar]
  44. Poli E., Casoli C., Spaggiari I., Starcich R., Bertaccini G. Contractile effect of endothelin-2 on the isolated human saphenous vein. Arch Int Pharmacodyn Ther. 1991 Sep-Oct;313:108–119. [PubMed] [Google Scholar]
  45. Sakurai T., Yanagisawa M., Takuwa Y., Miyazaki H., Kimura S., Goto K., Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 1990 Dec 20;348(6303):732–735. doi: 10.1038/348732a0. [DOI] [PubMed] [Google Scholar]
  46. Seo B., Oemar B. S., Siebenmann R., von Segesser L., Lüscher T. F. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation. 1994 Mar;89(3):1203–1208. doi: 10.1161/01.cir.89.3.1203. [DOI] [PubMed] [Google Scholar]
  47. Simonet S., Bonhomme E., Laubie M., Thurieau C., Fauchère J. L., Verbeuren T. J. Venous and arterial endothelial cells respond differently to thrombin and its endogenous receptor agonist. Eur J Pharmacol. 1992 May 27;216(1):135–137. doi: 10.1016/0014-2999(92)90222-p. [DOI] [PubMed] [Google Scholar]
  48. Sudjarwo S. A., Hori M., Tanaka T., Matsuda Y., Okada T., Karaki H. Subtypes of endothelin ETA and ETB receptors mediating venous smooth muscle contraction. Biochem Biophys Res Commun. 1994 Apr 15;200(1):627–633. doi: 10.1006/bbrc.1994.1494. [DOI] [PubMed] [Google Scholar]
  49. Sumner M. J., Cannon T. R., Mundin J. W., White D. G., Watts I. S. Endothelin ETA and ETB receptors mediate vascular smooth muscle contraction. Br J Pharmacol. 1992 Nov;107(3):858–860. doi: 10.1111/j.1476-5381.1992.tb14537.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Tanaka T., Tsukuda E., Nozawa M., Nonaka H., Ohno T., Kase H., Yamada K., Matsuda Y. RES-701-1, a novel, potent, endothelin type B receptor-selective antagonist of microbial origin. Mol Pharmacol. 1994 Apr;45(4):724–730. [PubMed] [Google Scholar]
  51. Teerlink J. R., Breu V., Sprecher U., Clozel M., Clozel J. P. Potent vasoconstriction mediated by endothelin ETB receptors in canine coronary arteries. Circ Res. 1994 Jan;74(1):105–114. doi: 10.1161/01.res.74.1.105. [DOI] [PubMed] [Google Scholar]
  52. Topouzis S., Huggins J. P., Pelton J. T., Miller R. C. Modulation by endothelium of the responses induced by endothelin-1 and by some of its analogues in rat isolated aorta. Br J Pharmacol. 1991 Feb;102(2):545–549. doi: 10.1111/j.1476-5381.1991.tb12208.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Tschirhart E. J., Drijfhout J. W., Pelton J. T., Miller R. C., Jones C. R. Endothelins: functional and autoradiographic studies in guinea pig trachea. J Pharmacol Exp Ther. 1991 Jul 1;258(1):381–387. [PubMed] [Google Scholar]
  54. Warner T. D., Allcock G. H., Corder R., Vane J. R. Use of the endothelin antagonists BQ-123 and PD 142893 to reveal three endothelin receptors mediating smooth muscle contraction and the release of EDRF. Br J Pharmacol. 1993 Oct;110(2):777–782. doi: 10.1111/j.1476-5381.1993.tb13879.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Warner T. D., Allcock G. H., Mickley E. J., Corder R., Vane J. R. Comparative studies with the endothelin receptor antagonists BQ-123 and PD 142893 indicate at least three endothelin receptors. J Cardiovasc Pharmacol. 1993;22 (Suppl 8):S117–S120. doi: 10.1097/00005344-199322008-00032. [DOI] [PubMed] [Google Scholar]
  56. Warner T. D., de Nucci G., Vane J. R. Rat endothelin is a vasodilator in the isolated perfused mesentery of the rat. Eur J Pharmacol. 1989 Jan 17;159(3):325–326. doi: 10.1016/0014-2999(89)90167-2. [DOI] [PubMed] [Google Scholar]
  57. Webb M. L., Liu E. C., Monshizadegan H., Chao C. C., Lynch J., Fisher S. M., Rose P. M. Expression of endothelin receptor subtypes in rabbit saphenous vein. Mol Pharmacol. 1993 Nov;44(5):959–965. [PubMed] [Google Scholar]
  58. White D. G., Garratt H., Mundin J. W., Sumner M. J., Vallance P. J., Watts I. S. Human saphenous vein contains both endothelin ETA and ETB contractile receptors. Eur J Pharmacol. 1994 May 23;257(3):307–310. doi: 10.1016/0014-2999(94)90144-9. [DOI] [PubMed] [Google Scholar]
  59. Willette R. N., Zhang H., Mitchell M. P., Sauermelch C. F., Ohlstein E. H., Sulpizio A. C. Nonpeptide endothelin antagonist. Cerebrovascular characterization and effects on delayed cerebral vasospasm. Stroke. 1994 Dec;25(12):2450–2456. doi: 10.1161/01.str.25.12.2450. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES